Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months

June 23, 2026 - 04:50

As the biotech industry gathers in San Diego for the BIO International Convention, the Department of Health and Human Services has released a series of initiatives aimed at accelerating early-stage drug development. The new plan targets a reduction in the timeline for phase 1 clinical trials by six to twelve months. Officials stated the move is designed to help the United States regain ground against China's rapidly expanding capabilities in early-stage clinical research.

The strategy focuses on streamlining regulatory processes and improving coordination between federal agencies. By cutting down the time it takes to move a candidate drug from the lab into first-in-human testing, the government hopes to make the U.S. a more attractive destination for innovative therapies. The announcement comes at a time when China has been investing heavily in its biotech infrastructure, shortening its own trial start times and attracting global investment.

Industry leaders at the convention expressed cautious optimism. Many noted that while faster approvals are welcome, the success of the plan will depend on maintaining rigorous safety standards. The HHS emphasized that the goal is not to lower the bar for safety, but to remove bureaucratic bottlenecks that do not contribute to patient protection. Specific details on which regulatory steps will be modified are expected in the coming weeks.